China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (MNPA) has accepted a market approval filing for its SPH3127, a Category 1 drug co-developed with Japan-based Mitsubishi Tanabe Pharma Corporation. The intended indication for this novel drug is hypertension.
SPH3127: A Novel Oral Renin Inhibitor in Clinical Development
SPH3127 is an innovative oral renin inhibitor that is currently undergoing a Phase II study in diabetic nephropathy in China and a separate Phase II study in mild to moderate ulcerative colitis (UC) in the US. This drug represents a significant advancement in the treatment of hypertension and related conditions, with the potential to offer new therapeutic options for patients.
Positive Results from Phase III Clinical Study
A Phase III clinical study for SPH3127 in primary hypertension was concluded in May 2023, yielding positive results. This successful trial outcome positions SPH3127 as a promising candidate for the treatment of hypertension, a condition that affects a significant portion of the global population.-Fineline Info & Tech
